

PRESS RELEASE 2024-03-11

Insider trading in subscription option TO1 - CEO Jonas Jönmark increases his stake in AcuCort AB

During the ongoing exercise period for subscription option TO1, AcuCort's CEO Jonas Jönmark has purchased 250,000 subscription options with the intention to convert them into shares during the TO period.

AcuCort announces that CEO Jonas Jönmark has purchased 250,000 subscription options on Spotlight Stock Market for a total amount of 3,750 SEK, corresponding to an average price of 0.015 SEK per subscription option TO1.

"Through the acquisition of subscription options, I have the opportunity to strengthen my ownership position in AcuCort ahead of the company's launch of the oral film Zeqmelit®," says Jonas Jönmark, CEO of AcuCort.

Jonas Jönmark's total holdings amount to 61,623 shares and 284,040 subscription options.

Summary of terms for subscription options of series TO1:

Terms: One (1) subscription option of series TO1 entitles the holder to subscribe for one (1) new share in AcuCort. Subscription price: 0.40 SEK per newly subscribed share.

Exercise period: March 6 - March 20, 2024.

For further information:

Jonas Jönmark, CEO AcuCort AB

Tel: +46 70 3655400

Email: jonas.jonmark@acucort.seAbout AcuCort AB (publ)

AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.